Overview

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Status:
Recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Bevacizumab
Cetuximab